Company: Teva Pharmaceuticals
Drug Type: Small Molecule
Conditions: ALS, Parkinson’s Disease
Mechanism Type: Mitochondrial Protectant
Mechanism: Rasagiline is an inhibitor of type B monoamine oxidase (MAO-B). It is thought to help protect neurons by bolstering mitochondria by suppressing Ca(2+) efflux through the mitochondrial permeability transition pore (Wu et al., 2015).
U.S. Status for ALS: Phase II
 Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) ClinicalTrials.gov, 14 Jun 2017. Accessed on 20 Feb 2018 from https://www.clinicaltrials.gov/ct2/show/NCT01786603
 Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis ClinicalTrials.gov, 25 Oct 2016. Accessed on 20 Feb 2018 from https://www.clinicaltrials.gov/ct2/show/NCT01879241
 Rasagiline and selegiline suppress calcium efflux from mitochondria by PK11195-induced opening of mitochondrial permeability transition pore: a novel anti-apoptotic function for neuroprotection. Wu, Y. et al. J Neural Transm (Vienna). 2015 Oct;122(10):1399-407.
Last updated February 20th, 2018